HC Wainwright Reaffirms Buy Rating for Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $7.50 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 323.73% from the stock’s […]